Please login to the form below

Not currently logged in
Email:
Password:

HCV

This page shows the latest HCV news and features for those working in and with pharma, biotech and healthcare.

Gilead unveils plan to separate Kite cell therapy unit

Gilead unveils plan to separate Kite cell therapy unit

O’Day’s mission is to revitalise Gilead after a tricky few years marked by a massive decline in sales for its hepatitis C virus (HCV) drugs, which continued to fall ... There has been concern for some time about Gilead’s reliance on HCV and HIV

Latest news

  • Gilead gets 'gold' in England's hepatitis C eradication drive Gilead gets 'gold' in England's hepatitis C eradication drive

    Over 30, 000 people in England have already benefited from from the HCV treatments since Gilead launched the first, Sovaldi, in Europe in 2014. ... However sales of the drugs have dropped off dramatically as finding the remaining patients with HCV, which

  • First-in-class hepatitis B/D drug raises cure hope First-in-class hepatitis B/D drug raises cure hope

    A new generation of directly-acting antivirals for hepatitis C virus (HCV) have made chronic infections effectively curable in almost all cases, but patients with chronic hepatitis B virus (HBV) infection

  • Pfizer closes on EU approval of lung cancer drug Vizimpro Pfizer closes on EU approval of lung cancer drug Vizimpro

    AbbVie’s Maviret (glecaprevir/pibrentasvir) got the nod for the treatment of chronic hepatitis C virus (HCV) infection in adults and in adolescents aged 12 and above.

  • NHS England sees off AbbVie's Hep C legal challenge NHS England sees off AbbVie's Hep C legal challenge

    eliminate HCV, with a target date of 2025, and spending £1bn over five years to achieve this goal. ... It was also critical of AbbVie’s challenge, saying it had caused an unnecessary six month delay to the start of the HCV elimination programme.

  • Roche's O’Day swaps big pharma for big biotech Roche's O’Day swaps big pharma for big biotech

    The new CEO's main task will be to ensure the company's revenues can grow again, as its once-record-breaking hepatitis C (HCV) franchise continues to decline sharply: in ... O’Day joins Gilead as the big biotech company is on the hunt for new drugs to

More from news
Approximately 8 fully matching, plus 117 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    HCV). As Gilead’s patent estate around these compounds is being challenged around the world, this appears to be a strategy of getting their response in first, and fending off both

  • Pharma deals in May 2015 Pharma deals in May 2015

    The agreement covers ACH 3102, ACH 3422 and sovaprevir. The intention is to trial a combination of ACH 3102 with a NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase

  • AbbVie: New firm, new thinking AbbVie: New firm, new thinking

    virus (HCV) to help navigate the care system and make the most of new treatments. ... And obviously the NHS saves on downstream costs associated with HCV, such as liver disease and the prospect of liver transplants.

  • Communicating value Communicating value

    We are seeing instances, eg in HCV, where simple affordability, rather than cost effectiveness, is a major factor in spending decisions.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    42, 900. Idenix Pharmaceuticals/ Merck &Co. Company acquisition. Hepatitis C assets include IDX21437 (p1/2 nucleotide inhibitor) to combine with Merck HCV drugs. ... 75. Orion/ Bayer. Co-development, option to co-promote in Europe. OraQuick HCV rapid

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 8 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Playing Mind Games
To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists
P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....

Infographics